Zol reverses the epithelial-mesenchymal transition (EMT) and growth of cancer cells through inactivation of nuclear factor (NF)-κB [11], and Zol inhibits osteoclastogenesis and bone resorption by suppressing receptor activator of NF-κB ligand (RANKL)‐mediated NF‐κB signaling. The gene discussed is NFKB1; the disease is cancer.